Horizon Therapeutics Announces 79% Of Patients Achieved A Complete Response In MIRROR Open-Label Pilot Study, Supporting KRYSTEXXA Immunomodulation Strategy To Optimize Treatment Outcomes

Benzinga · 01/13/2020 13:22